Leukemia, Myeloid, Acute Clinical Trial
Official title:
Phase 1B Study of PTC299 in Relapsed/Refractory Acute Leukemias
This is an open-label, non-randomized, Phase 1b study to evaluate the safety, pharmacokinetics (PK) profiles, and preliminary evidence of antitumor activity of PTC299 and the metabolite, O-desmethyl PTC299, in participants with relapsed/refractory acute myeloid leukemia (AML) who have exhausted standard available therapies known to provide clinical benefit. The study is designed as a series of cohort-based dose escalations. For each cohort, a minimum of 3 evaluable participants with PK and safety data will be assessed. Additional participants will be recruited if additional PK data are needed to assess mean exposure based on the observed variability.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05319587 -
Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04090736 -
Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy
|
Phase 3 | |
| Completed |
NCT01617226 -
Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS
|
Phase 2 | |
| Terminated |
NCT00916045 -
Pilot Study of Unrelated Cord Blood Transplantation
|
Phase 2 | |
| Terminated |
NCT00957580 -
Trial of Pimasertib in Hematological Malignancies
|
Phase 2 | |
| Completed |
NCT00640796 -
Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors
|
Phase 1 | |
| Completed |
NCT00458250 -
Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H
|
Phase 1 | |
| Active, not recruiting |
NCT05424380 -
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS
|
Phase 1 | |
| Completed |
NCT01690624 -
BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse
|
Phase 1 | |
| Recruiting |
NCT05471700 -
Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05016063 -
Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
|
Early Phase 1 | |
| Not yet recruiting |
NCT04450784 -
ObServatory Children Acute RElated Therapy Leukemia
|
||
| Recruiting |
NCT04265963 -
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Terminated |
NCT04968860 -
Oral Health Condition and Quality of Life in Children With Leukemia
|
||
| Recruiting |
NCT03793517 -
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
|
Phase 2/Phase 3 | |
| Terminated |
NCT02841540 -
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
|
Phase 1 | |
| Recruiting |
NCT05453903 -
A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
|
Phase 1 | |
| Completed |
NCT03720366 -
A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients
|
Phase 1 | |
| Withdrawn |
NCT04230564 -
Acute Myeloid Leukemia Real World Treatment Patterns
|
||
| Completed |
NCT01835587 -
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).
|
Phase 1/Phase 2 |